Issues with reporting and interpretation of Khan et al. 2021
Abstract A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. Thes...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07551-8 |
| _version_ | 1811333833678651392 |
|---|---|
| author | Nicholas J. DeVito Henry Drysdale |
| author_facet | Nicholas J. DeVito Henry Drysdale |
| author_sort | Nicholas J. DeVito |
| collection | DOAJ |
| description | Abstract A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading. |
| first_indexed | 2024-04-13T16:58:42Z |
| format | Article |
| id | doaj.art-73b4ce7bcd63409fb97afc8d2fbb42ef |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-13T16:58:42Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-73b4ce7bcd63409fb97afc8d2fbb42ef2022-12-22T02:38:44ZengBMCBMC Infectious Diseases1471-23342022-06-012211310.1186/s12879-022-07551-8Issues with reporting and interpretation of Khan et al. 2021Nicholas J. DeVito0Henry Drysdale1Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterAbstract A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.https://doi.org/10.1186/s12879-022-07551-8Trials TransparencyTrial ReportingTrial RegistrationConvalescent PlasmaCovid-19 |
| spellingShingle | Nicholas J. DeVito Henry Drysdale Issues with reporting and interpretation of Khan et al. 2021 BMC Infectious Diseases Trials Transparency Trial Reporting Trial Registration Convalescent Plasma Covid-19 |
| title | Issues with reporting and interpretation of Khan et al. 2021 |
| title_full | Issues with reporting and interpretation of Khan et al. 2021 |
| title_fullStr | Issues with reporting and interpretation of Khan et al. 2021 |
| title_full_unstemmed | Issues with reporting and interpretation of Khan et al. 2021 |
| title_short | Issues with reporting and interpretation of Khan et al. 2021 |
| title_sort | issues with reporting and interpretation of khan et al 2021 |
| topic | Trials Transparency Trial Reporting Trial Registration Convalescent Plasma Covid-19 |
| url | https://doi.org/10.1186/s12879-022-07551-8 |
| work_keys_str_mv | AT nicholasjdevito issueswithreportingandinterpretationofkhanetal2021 AT henrydrysdale issueswithreportingandinterpretationofkhanetal2021 |